CirculationAdultAgedFemaleHumansMale
Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial.
Marcely Gimenes Bonatto, Mônica Samuel Avila, Sílvia Moreira Ayub Ferreira, Luka David Lechinewski, Rafael de Almeida Torres, Amanda de Nadai Costa, Nadya Rocumback Alves da Costa, Andressa de Oliveira Coiradas, Talita Beithum Ribeiro Mialski, Julyana Maiolino, Tammy Tiemy Ota, Laís Contin, Larissa Arlete Mosko, Marcio Sommer Bittencourt, Sanderson Cauduro
Published: 202510.1161/CIRCULATIONAHA.125.073322
Abstract
BACKGROUND: The clinical effects of sacubitril-valsartan, an angiotensin receptor-neprilysin inhibitor, on anthracycline-induced cardiotoxicity remain unknown. Experimental evidence suggests cardioprotective properties. This study evaluated the effic…
Preview only. Read the full abstract at the source